
The IPF market is expected to witness a significant shift thanks to the positive outcomes of several products during the developmental stage by key players such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
The IPF market report from DelveInsight provides current treatment practices, IPF emerging drugs, IPF market share of the individual therapies, current and forecasted 7MM IPF market size from 2019 to 2032. The report also covers current IPF treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Key takeaways from the IPF market research report:• The increase in IPF market size is a direct consequence of expected approval of emerging therapy and increasing patient population of IPF in the four countries.
• In DelveInsight's epidemiology forecast model of IPF, we have first calculated the diagnosed prevalent cases of IPF. These IPF cases are further bifurcated into gender-specific, age-specific and severity-specific cases.
• The analysis found that males predominantly have the higher number of diagnosed prevalent cases than females. In 2021, 15,446 males and 5,800 females were affected by IPF in Japan.
• The IPF market companies includes FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others. • Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies includes ESBRIET (Pirfenidone), OFEV (Nintedanib), Pamrevlumab, PRM-151 (RG6354), Tyvaso (inhaled treprostinil), BI 1015550, PLN-74809, GB0139, and others.
IPF is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle-aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking.
The therapeutic approach of IPF involves both non pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations and prolong the survival. There are two antifibrotic agents Esbriet (Roche) and OFEV (Boehringer Ingelheim) popular for treating IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.
Emerging therapies for the treatment of IPF include a great deal of emerging drug Pamrevlumab, PRM-151, Tyvaso (treprostinil) and others. Therapies in the pipeline have the potential to change the market size and manage the disease burden and progression. Overall, the increasing awareness of the disease assisted by organizational support along with the high prices of existing therapies and the entry of some new products is expected to fuel the market size during the forecasted period of 2022-2032.
Click here for the IPF Market Research Report.